Octozi vs QuantHealth (2026)
Octozi works inside a running trial. Its AI agents handle data cleaning, medical data review, safety review and reconciliation, medical monitoring and clinical operations across five modules, harmonizing EDC, safety, laboratory, CTMS, eCOA and IRT data and drafting queries that reviewers accept, edit or reject. Its models are fine tuned from Llama 4, and the company says customer data never trains them. QuantHealth works before a trial starts. It predicts how patients would respond to an investigational therapy and rolls those predictions into a simulated result, so a sponsor can test protocol, indication and enrollment choices, and it publishes simulated against actual results for three phase 3 trials. Buy Octozi to run a study's data work with fewer hands; buy QuantHealth to decide which study to run.
- Agents for data cleaning, medical review, safety review, reconciliation and medical monitoring on one workspace.
- Queries a reviewer accepts, edits or rejects, traced back to the source system.
- SOC 2 Type II, with customer data held in separate environments and kept out of model training.
- Trial simulation for protocol, indication and enrollment choices before a study runs.
- Simulated against actual results published for three phase 3 trials.
- Probability of technical success and market forecasting from the same models.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Octozi and QuantHealth are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Octozi | QuantHealth |
|---|---|---|
| Primary category | Clinical Trials AI | Clinical Trials AI |
| Founded | 2024 | 2020 |
| Headquarters | New York, New York, United States | Tel Aviv, Israel |
| Website | octozi.com | quanthealth.ai |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
New York company applying AI agents to clinical trial data operations: data cleaning, medical data review, safety review and reconciliation, medical monitoring and clinical operations, across five modules on one workspace for the study team. It harmonizes EDC, safety, laboratory, CTMS, eCOA and IRT data with source traceability and pairs proprietary language models fine-tuned from Llama 4 with heuristic algorithms, flagging discrepancies and drafting queries that reviewers accept, edit or reject.
Source: AI Health Index, September 2026
Clinical trial simulation company with offices in Tel Aviv and Worcester, Massachusetts. Its platform predicts how individual patients would respond to an investigational therapy, drawing on a knowledge graph of drug biology and a real world database the company sizes at 350 million lives, and aggregates those predictions into a simulated trial result so sponsors can test protocol, indication and enrollment choices before a study runs.
Source: AI Health Index, September 2026
Questions buyers ask
How do Octozi and QuantHealth work with the EHR?
For Octozi, the platform harmonizes EDC, safety, laboratory, CTMS, eCOA and IRT data into one model with source traceability, and the company's positioning is to work with the systems study teams already use.
With QuantHealth, the company's data framework integrates biomedical, clinical and epidemiological sources on its side. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
Which settings and specialties do Octozi and QuantHealth cover?
In Octozi's case, the platform covers the clinical trial data layer (data management, clinical science review, safety review and reconciliation, medical monitoring and clinical operations) for pharmaceutical, biotech and medtech sponsors and contract research organizations. The only published evaluation used synthetic data built from one phase 3 oncology trial.
For QuantHealth, the evidence page claims coverage across therapeutic areas, clinical phases and treatment modalities, and case studies span oncology (head and neck, breast, multiple myeloma), inflammatory, metabolic and respiratory disease. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
How much do Octozi and QuantHealth leave to the clinician?
With Octozi, the company describes a human-in-the-loop design in which the platform flags discrepancies with a narrative rationale and drafts queries, and reviewers can modify or reject each suggestion before anything reaches a site; deterministic algorithms handle the parts that must be reproducible.
In QuantHealth's case, the results go to clinical development, business development and portfolio teams as virtual trial readouts, enrollment curves and probability of success estimates; nothing is actioned on a patient. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Trials AI page.
Both records were reviewed on this site in September 2026. Neither company publishes a price. Octozi's reported six fold faster review comes from a preprint using synthetic trial data and ten reviewers.
Ask Octozi how its accuracy holds on real trial data, and ask QuantHealth how many of its predictions have been checked against readouts.